Binds A Receptor (e.g., Transferrin Receptor, Fc Receptor, Dihydropyridine Receptor, Il-2 Receptor, Etc.) Patents (Class 435/334)
-
Publication number: 20130108546Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: Neotope Biosciences LimitedInventor: Neotope Biosciences Limited
-
Publication number: 20130109087Abstract: The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins.Type: ApplicationFiled: October 10, 2012Publication date: May 2, 2013Applicants: EOTVOS LORAND UNIVERSITY, AGRICULTURAL BIOTECHNOLOGY CENTERInventors: AGRICULTURAL BIOTECHNOLOGY CENTER, Eotvos Lorand University
-
Publication number: 20130108650Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.Type: ApplicationFiled: October 27, 2011Publication date: May 2, 2013Applicant: Acceleron Pharma, Inc.Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
-
Publication number: 20130108641Abstract: The invention provides antibodies that specifically bind to human GITR (hGITR) with high affinity and antagonize the binding of hGITRL to hGITR. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-GITR antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to detect hGITR or to modulate hGITR activity, either in vitro or in vivo, are also provided by the invention.Type: ApplicationFiled: September 12, 2012Publication date: May 2, 2013Applicant: SANOFIInventors: Nicolas Baurin, Francis Blanche, Béatrice Cameron, Tarik Dabdoubi, Jeremy Fordham, Dorothea Kominos, Jacintha Norohna, Tim Soos
-
Publication number: 20130089560Abstract: The present invention provides bone morphogenetic protein receptor (BMPR) binding agents, such as antibodies, and compositions comprising said binding agents. The binding agents are useful to treat diseases such as cancer.Type: ApplicationFiled: March 17, 2011Publication date: April 11, 2013Applicant: OncoMed Pharmaceuticals IncInventors: Cecile Chartier-Courtaud, Austin L. Gurney
-
IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS
Publication number: 20130084243Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.Type: ApplicationFiled: November 29, 2012Publication date: April 4, 2013Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Publication number: 20130078717Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: MedImmune LimitedInventors: Jamie Iain CAMPBELL, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20130078675Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R).Type: ApplicationFiled: November 16, 2012Publication date: March 28, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130071397Abstract: The present invention provides moieties that bind to the most membrane-proximal Ig-like domain of the ectodomain (D7) of vascular endothelial growth factor (VEGF) receptors, wherein the moieties antagonize the activity of the VEGF receptor.Type: ApplicationFiled: December 20, 2010Publication date: March 21, 2013Applicant: YALE UNIVERSITYInventors: Joseph Schlessinger, Yan Yang
-
Publication number: 20130039850Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.Type: ApplicationFiled: July 9, 2012Publication date: February 14, 2013Applicant: GENPHARM INTERNATIONAL, INC.Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
-
Publication number: 20130039907Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Applicant: KaloBios Pharmaceuticals Inc.Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
-
Publication number: 20130030155Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: ApplicationFiled: May 15, 2012Publication date: January 31, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
-
Patent number: 8361468Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: August 20, 2012Date of Patent: January 29, 2013Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
-
Publication number: 20130024956Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20130023047Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.Type: ApplicationFiled: September 19, 2012Publication date: January 24, 2013Applicants: Genentech, Inc. A member of the Roche Group, SEATTLE GENETICS, INC.Inventors: Seattle Genetics, Inc., Genentech, Inc. A member of the Roche Group
-
Publication number: 20130017195Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Inventor: Daniel John O'Shannessy
-
Publication number: 20130004513Abstract: Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.Type: ApplicationFiled: May 30, 2012Publication date: January 3, 2013Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Holger Wallmeier, Kirsten Völp, Gregor Schulz
-
Publication number: 20130005949Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 3, 2011Publication date: January 3, 2013Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
-
Publication number: 20120328616Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.Type: ApplicationFiled: June 1, 2012Publication date: December 27, 2012Applicant: AMGEN INC.Inventors: YANG LI, Jennitte STEVENS, Chadwick Terence KING, Ian FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
-
Publication number: 20120328511Abstract: Antigen binding proteins, such as antibodies, that interact with Epidermal Growth Factor Receptor (EGFR) are described. Methods of treating cancers and other diseases by administering a pharmaceutically effective amount of an antigen binding protein to EGFR are also described.Type: ApplicationFiled: April 6, 2012Publication date: December 27, 2012Applicant: AMGEN INC.Inventor: Amy Y. GUO
-
Publication number: 20120329063Abstract: The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.Type: ApplicationFiled: August 15, 2012Publication date: December 27, 2012Applicant: INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M)Inventors: ARMAND BENSUSSAN, Martine Bagot, Laurence Boumsell, Allessandro Moretta
-
Publication number: 20120329997Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 3, 2011Publication date: December 27, 2012Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
-
Publication number: 20120321643Abstract: The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10?10 mol/L) and are able to inhibit the growth and migration of tumor cells.Type: ApplicationFiled: December 30, 2009Publication date: December 20, 2012Applicant: GUANGZHOU RECOMGEN BIOTECH CO., LTD.Inventors: David Weaver, Michael Rynkiewicz, Cheng Cao, Yanwen Jin
-
Publication number: 20120309031Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed.Type: ApplicationFiled: July 6, 2012Publication date: December 6, 2012Applicant: CELLDEX THERAPEUTICS INC.Inventors: Tibor KELER, Lizhen HE, Venky RAMAKRISHNA, Laura A. VITALE
-
Patent number: 8309315Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: GrantFiled: August 25, 2008Date of Patent: November 13, 2012Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research CenterInventors: Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
-
Publication number: 20120282637Abstract: The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.Type: ApplicationFiled: October 8, 2010Publication date: November 8, 2012Applicant: SANOFIInventors: Jochen Huber, Francis Blanche, Tarik Dabdoubi, Fabienne Soubrier, Ingo Focken, Jochen Kruip, Kathrin Heermeier, Christian Lange
-
Publication number: 20120270268Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.Type: ApplicationFiled: June 14, 2012Publication date: October 25, 2012Applicant: Vaccinex, Inc.Inventors: Ernest S. SMITH, Terrence Lee Fisher
-
Publication number: 20120258122Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: June 15, 2012Publication date: October 11, 2012Inventors: Thomas C. Boone, Jonathan D. Oliner
-
Publication number: 20120253019Abstract: Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab?)2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.Type: ApplicationFiled: July 12, 2011Publication date: October 4, 2012Applicant: B.R.A.H.M.S GMBHInventors: Andreas BERGMANN, Nils G. MORGENTHALER, Gilbert VASSART, Sabine COSTAGLIOLA
-
Publication number: 20120251555Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: November 29, 2011Publication date: October 4, 2012Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
-
Patent number: 8278090Abstract: The invention discloses novel methods of producing hydrocarbons through heterotrophic cultivation of Botryococcus braunii. Also provided are novel hydrocarbon compositions. A preferred species for engineering is the microalgae species Botryococcus braunii. Additional methods of cultivation include providing certain nutrient sources.Type: GrantFiled: July 2, 2009Date of Patent: October 2, 2012Assignee: Solazyme, Inc.Inventors: Chung-Soon Im, Diana Vincent, Rika Regentin, Anna Coragliotti
-
Patent number: 8277808Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof that bind naturally occurring human MAdCAM, wherein said naturally occurring human MAdCAM comprises a polypeptide with at least 90% sequence identity to SEQ ID NO:2 or SEQ ID NO:4, said naturally occurring human MAdCAM binds ?4?7, and wherein said isolated antibodies and antigen-binding fragments thereof inhibit binding of said naturally occurring human MAdCAM to human ?4?7, and wherein said antibody inhibits adhesion of RPMI 8866 cells to cells that express said human MAdCAM.Type: GrantFiled: April 3, 2007Date of Patent: October 2, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventor: Michael J. Briskin
-
Patent number: 8273541Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: GrantFiled: September 15, 2009Date of Patent: September 25, 2012Assignee: Innate PharmaInventors: Karine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Patent number: 8268592Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: July 17, 2009Date of Patent: September 18, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Publication number: 20120231021Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: ApplicationFiled: November 2, 2009Publication date: September 13, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo
-
Publication number: 20120225064Abstract: Materials and Method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of sphingosine-1-phosphate receptor subtype 3 are provided.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: EXPRESSION DRUG DESIGNS, LLCInventors: Deron R. HERR, Greg L. HARRIS
-
Publication number: 20120225013Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: December 19, 2011Publication date: September 6, 2012Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
-
Patent number: 8252584Abstract: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.Type: GrantFiled: June 3, 2011Date of Patent: August 28, 2012Assignees: Toudai TLO, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takashi Kadowaki, Toshimasa Yamauchi, Ryozo Nagai, Junji Kamon
-
Publication number: 20120213771Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: October 19, 2011Publication date: August 23, 2012Applicant: CELLDEX THERAPEUTICS INC.Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
-
Publication number: 20120192296Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.Type: ApplicationFiled: March 30, 2010Publication date: July 26, 2012Applicants: Universite de Lausanne, Edimer Biotech S.A.Inventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
-
Publication number: 20120189639Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: ApplicationFiled: August 31, 2010Publication date: July 26, 2012Applicant: Schering CorporationInventors: Xiao Min Schebye, Grigory P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Publication number: 20120189643Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: ApplicationFiled: March 5, 2012Publication date: July 26, 2012Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
-
Patent number: 8226943Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: July 8, 2009Date of Patent: July 24, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20120183565Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.Type: ApplicationFiled: July 26, 2010Publication date: July 19, 2012Applicants: N.V. ORGANON, MEDAREX, INC.Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
-
Publication number: 20120177659Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
-
Publication number: 20120164159Abstract: A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.Type: ApplicationFiled: July 6, 2010Publication date: June 28, 2012Applicant: OPSONA THERAPEUTICS LIMITEDInventor: Jerome Dellacasagrande
-
Publication number: 20120164161Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: December 7, 2011Publication date: June 28, 2012Applicant: AFFITECH RESEARCH ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
-
Publication number: 20120156217Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: October 28, 2011Publication date: June 21, 2012Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Publication number: 20120148572Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.Type: ApplicationFiled: May 20, 2011Publication date: June 14, 2012Applicant: Genentech, Inc.Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye